- Home
- MEIP vs GRFX Comparison
MEIP vs GRFX Comparison
Compare MEIP & GRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- GRFX
- Stock Information
- Founded
- MEIP 2000
- GRFX 1981
- Country
- MEIP United States
- GRFX Hong Kong
- Employees
- MEIP N/A
- GRFX N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- GRFX
- Sector
- MEIP Health Care
- GRFX
- Exchange
- MEIP Nasdaq
- GRFX Nasdaq
- Market Cap
- MEIP 17.1M
- GRFX 18.1M
- IPO Year
- MEIP 2003
- GRFX N/A
- Fundamental
- Price
- MEIP $2.15
- GRFX $1.12
- Analyst Decision
- MEIP Hold
- GRFX Hold
- Analyst Count
- MEIP 2
- GRFX 1
- Target Price
- MEIP $7.00
- GRFX N/A
- AVG Volume (30 Days)
- MEIP 8.3K
- GRFX 34.9K
- Earning Date
- MEIP 05-08-2025
- GRFX 01-01-0001
- Dividend Yield
- MEIP N/A
- GRFX N/A
- EPS Growth
- MEIP N/A
- GRFX N/A
- EPS
- MEIP N/A
- GRFX N/A
- Revenue
- MEIP N/A
- GRFX $24,184,100.00
- Revenue This Year
- MEIP N/A
- GRFX N/A
- Revenue Next Year
- MEIP N/A
- GRFX N/A
- P/E Ratio
- MEIP N/A
- GRFX N/A
- Revenue Growth
- MEIP 33.76
- GRFX N/A
- 52 Week Low
- MEIP $2.15
- GRFX $0.71
- 52 Week High
- MEIP $4.11
- GRFX $2.75
- Technical
- Relative Strength Index (RSI)
- MEIP 27.69
- GRFX 47.41
- Support Level
- MEIP $2.28
- GRFX $0.90
- Resistance Level
- MEIP $2.35
- GRFX $1.73
- Average True Range (ATR)
- MEIP 0.07
- GRFX 0.24
- MACD
- MEIP -0.00
- GRFX -0.00
- Stochastic Oscillator
- MEIP 0.00
- GRFX 33.13
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About GRFX Graphex Group Limited each representing 20
Graphex Group Ltd is engaged in the sale of graphene products. It operates in three segments namely, the Graphene Products Segment includes Processing and sale of graphite and graphene-related products; the Landscape Architecture Design Segment includes Providing landscape architecture design; and the catering business focuses on the operation of restaurants. The company derives the majority of its revenue from the sale of graphene products segment.